top of page

Lundbeck CEO Charl van Zyl describes the rationale for today's $2.6 billion acquisition of Longboard Pharma

  • blonca9
  • Oct 14, 2024
  • 1 min read

He explains the market opportunity he sees for Bexicaserin and the data that made him comfortable to pull the trigger on the deal today ahead of a phase 3 study.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page